Circulating microparticles in carriers of prothrombin G20210A mutation

Elena Campello; Luca Spiezia; Claudia M. Radu; Sabrina Gavasso; Patrizia Zerbinati; Barry Woodhams; Paolo Simioni

doi:10.1160/TH13-12-1006

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 112(03): 432-437
DOI: 10.1160/TH13-12-1006

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Circulating microparticles in carriers of prothrombin G20210A mutation

Elena Campello

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

,

Luca Spiezia

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

,

Claudia M. Radu

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

,

Sabrina Gavasso

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

,

Patrizia Zerbinati

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

,

Barry Woodhams

²HaemaCon Ltd, Bromley, Kent, UK

,

Paolo Simioni

¹Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, Thrombosis and Haemostasis Unit, University of Padua, Italy

› Institutsangaben

Abstract

Summary

Factor V Leiden (FVL) and prothrombin gene mutation G20210A (PTM) are the two most common genetic polymorphisms known to predispose carriers to venous thromboembolism (VTE). A recent study in FVL carriers showed that circulating levels of microparticles (MP) may contribute to their thrombogenic profile. To further elucidate the prothrombotic state linked to genetic thrombophilia, we extended this study to carriers of PTM. The plasma level of annexin V-MP, endothelial- MP (EMP), platelet-MP (PMP), tissue factor-bearing MP (TF+) and the MP procoagulant activity (PPL) was measured in 124 carriers of PTM (105 heterozygous and 19 homozygous) and in 120 age- and gender-matched healthy individuals. Heterozygous and homozygous carriers of PTM showed significantly increased levels of annexin V-MP (2930 [1440–4646] MP/μl and 3064 [2412–4906] MP/μl, respectively) and significantly shorter PPL clotting time (54 [46–67] sec and 55 [46–64] sec) compared to controls (1728 [782–2122] MP/μl and 71 [61–75] sec, respectively; p<0.01). Similarly, heterozygous and homozygous subjects presented with significantly higher levels of EMP, PMP and TF+ than controls (p<0.05). PTM carriers with a VTE history had significantly higher MP numbers and activity than controls. No significant difference was seen between carriers with and without a VTE history. We conclude that the higher levels of circulating MP found in PTM carriers may play a role in the development of VTE possibly by increasing thrombin generation. Further studies are needed to better define the role of MP as triggering factors for the thrombotic complications characterizing mild genetic thrombophilic defects.

Keywords

Hypercoagulability - microparticles - thrombophilia - venous thrombosis

Volltext

Referenzen

References
1 Bauer KA. The thrombophilias: well defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-373.
2 Marchiori A, Mosena L, Prins HM. et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
3 Simioni P, Tormene D, Spiezia L. et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 700-708.
4 Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003; 138: 128-134.
5 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
6 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
7 Tormene D, Simioni P, Pagnan A. et al. The G20210A prothrombin gene mutation: is there room for screening families?. J Thromb Haemost 2004; 2: 1487-1488.
8 Martinelli I, Bucciarelli P, Margaglione M. et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-1229.
9 Ridker PM, Hennekens CH, Miletich J. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
10 Cattaneo M, Chantarangkul V, Taioli E. et al. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylene-tetrahydrofolatereductase C677T and plasma prothrombin levels. Thromb Res 1998; 93: 1-8.
11 Segers O, Simioni P, Tormene D. et al. Genetic Modulation of the FV(Leiden) /normal FV Ratio and Risk of Venous Thrombosis in FV Leiden Heterozygotes. J Thromb Haemost 2012; 10: 73-80.
12 Simioni P, Tormene D, Luni S. et al. Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. Blood Coagul Fibrinolysis 2000; 11: 379-384.
13 Ay C, Freyssinet JM, Sailer T. et al. Circulating procoagulant microparticles in patients with venous thromboembolism. Thromb Res 2009; 123: 724-726.
14 Owens III AP, Mackman N. Microparticles in Hemostasis and Thrombosis. Circ Res 2011; 108: 1284-1297.
15 Ye R, Ye C, Huang Y. et al. Circulating tissue-factor positive microparticles in patients with acute recurrent deep vein thrombosis. Thromb Res 2012; 130: 253-258.
16 Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171.
17 Boulanger CM, Dignat-George F. Microparticles: an introduction. Arterioscler Thromb Vasc Biol 2011; 31: 2-3.
18 Morel O, Toti F, Hugel B. et al. Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
19 Burger D, Schock S, Thompson CS. et al. Microparticles: biomarkers and beyond. Clin Sci 2013; 124: 423-441.
20 Campello E, Spiezia L, Radu C. et al. Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. Thromb Haemost 2012; 108: 633-639.
21 Koutroumpi S, Spiezia L, Albiger N. et al. Thrombin generation in Cushing’s Syndrome: do the conventional clotting indices tell the whole truth?. Pituitary 2014; 17: 68-75.
22 Simioni P, Tormene D, Manfrin D. et al. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103: 1045-1050.
23 Campello E, Spiezia L, Radu CM. et al. Endothelial, platelet and tissue factor-bearing microparticles in cancer patients with and without venous thrombembolism. Thromb Res 2011; 127: 473-477.
24 Lacroix R, Robert S, Poncelet P. et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 08: 2571-2574.
25 Lacroix R, Judicone C, Mooberry M. et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013; 11: 1190-1193.
26 van Dreden P, Rousseau A, Fontaine S. et al. Monitoring patient plasma platelet derived procoagulantmicroparticles (PMP) with a new factor Xa-based clotting test (XaCT). Blood Coag Fibrinolysis 2009; 20: 494-502.
27 Noubouossie DC, Lê PQ, Rozen L. et al. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 2012; 130: 259-264.
28 Martinelli I, Bucciarelli P, Margaglione M De. et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-1229.
29 Eikelboom JW, Ivey L, Ivey J. et al. Familial thrombophilia and the prothrombin G20210A mutation: association with increase thrombin generation and unusual thrombosis. Blood Coag Fibrinolysis 1999; 10: 1-5.
30 Castoldi E, Simioni P, Tormene D. et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007; 05: 971-979.
31 Kyrle PA, Mannhalter C, Béguin S. et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-1291.
32 Lavigne-Lissalde G, Sanchez C, Castelli C. et al. Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost 2010; 08: 942-949.
33 Aleman MA, Walton BL, Byrnes JR. et al. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol 2013; 33: 1829-1836.